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Abstract: Accurate kidney function estimates are necessary when prescribing renally-eliminated
medications. Our objectives were to investigate how amputation affects estimated glomerular
filtration rate (eGFR) and to determine if dosing recommendations differ among different eGFR
equations. In a cohort study of non-traumatic amputation patients, eGFR based on creatinine
and/or cystatin C were measured before and after amputation. Prescribed, renally-eliminated
medications were compared with dosing guidelines in Renbase®. Data from 38 patients
with a median age of 75 years were analyzed. The median (range) eGFR was 65 (15–103),
38 (13–79), and 48 (13–86) mL/min/1.73 m2 before amputation and 80 (22–107), 51 (13–95), and
62 (16–100) mL/min/1.73 m2 after amputation for eGFRCreatinine, eGFRCystatinC, and eGFRCombined,
respectively (p < 0.01). From before to after amputation, eGFR increased on average by 8.5, 6.1, and
7.4 mL/min/1.73 m2 for eGFRCreatinine, eGFRCystatinC, and eGFRCombined (all p < 0.01), respectively.
At least one renally-eliminated medication was prescribed at a higher dose than recommended in
37.8% of patients using eGFRCystatinC, 17.6% using eGFRCombined and 10.8% using eGFRCreatinine.
In conclusion, amputation affects eGFR regardless of the eGFR equations. The differences among
equations would impact prescribing of renally-eliminated medications, particularly when switching
from creatinine to cystatin C.
Keywords: Creatinine; cystatin C; glomerular filtration rate; renal insufficiency; amputation; drug
therapy; drug dose adjustment; drug dosing; inappropriate prescribing
1. Introduction
Inappropriate drug prescribing is associated with adverse drug reactions, toxicity, and mortality [1].
Approximately 40% of all drugs or their active metabolites are excreted by the kidneys, posing a challenge
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for accurate dosing in patients with reduced kidney function [2]. These renally-eliminated medications
must be prescribed according to kidney function to optimize drug therapy. Previous observational
studies from hospital settings found that prescribing renally-eliminated medications at a dose higher
than that recommended by clinical guidelines occurs in up to two-thirds of patients [3–5]. Meanwhile,
a Swedish study concluded that one-third of all adverse drug reactions leading to hospitalizations
were related to improper dose adjustment according to the patient’s kidney function [6].
Patients undergoing non-traumatic lower extremity amputation (hereafter referred to as
amputation) are often poly-medicated and suffer from reduced kidney function [7]. Furthermore,
these patients have high rates of comorbid cardiovascular disease, diabetes, and inflammation, which
can accelerate the loss of kidney function. Typical medications for amputation patients include,
renally-eliminated medications, such as opioids, adjuvant analgesics, antithrombotic drugs, and
non-steroidal anti-inflammatory drugs [7], which highlight the importance of obtaining an accurate
measurement of kidney function for this group of patients.
Exogenous filtration markers such as inulin and iohexol are accurate measures of glomerular
filtration rate (GFR), but these “gold standards” are expensive, time-consuming, and not part of
standard clinical practice. Instead, GFR is typically estimated with an endogenous biomarker.
Creatinine is most frequently used worldwide as it is relatively simple and inexpensive to measure, and
sufficiently accurate for most adult patients. The Chronic Kidney Disease Epidemiology Collaboration
equation based on creatinine (CKD-EPICreatinine) is used worldwide to calculate estimated glomerular
filtration rate (eGFR). CKD-EPICreatinine is recommended by Kidney Disease.
Improving Global Outcome (KDIGO) and the Danish Society of Nephrology for standard
diagnosis and treatment of kidney disease [8,9], and it is commonly used for drug prescribing in
the clinic. The creatinine-based Cockcroft-Gault equation (CGCreatinine) developed in 1973 [10] also
continues to be used in pharmacokinetic studies during drug development [11] and sometimes
in clinical practice [12,13], despite its lack of performance [14]. However, creatinine is heavily
dependent on muscle mass, nutritional status, age, and sex [15–17]. Patients undergoing amputation
are at particularly high risk of incorrect estimation of kidney function based on creatinine, due to
malnutrition and loss of muscle mass [15,16,18,19], which may lead to inappropriate prescribing of
renally-eliminated medications.
Cystatin C is another endogenous biomarker, which is less dependent on age, sex and muscle
mass compared to creatinine [20] and, therefore, recommended for patients with low muscle mass [8,9].
A combined creatinine and cystatin C equation (CKD-EPICombined) is thought to be the most accurate
across a full range of GFRs and, in particular, patient subgroups [9,21–24], while the equation using
cystatin C alone (CKD-EPICystatinC) was as accurate as CKD-EPICombined in elderly patients with very
low BMI [25]. Another study concluded that cystatin C is preferable to creatinine, following traumatic
amputation in young soldiers [18]. However, no studies, to our knowledge, have focused on the impact
of amputation on eGFR and dose recommendations in non-traumatic amputation patients.
Our objectives in this study were: 1) to assess eGFR before and after amputation based on
CKD-EPICreatinine, CKD-EPICystatinC, and CKD-EPICombined, and 2) to estimate whether prescribing
recommendations for renally-eliminated medications and the number of inappropriate prescriptions
of renally-eliminated medications differ among the different CKD-EPI equations.
2. Methods and Materials
2.1. Study Design
This is a sub-study to the Time to Eat Study, a longitudinal, single-center cohort study, which aimed
to describe and measure the association between dietary intake and inflammation in patients with
non-traumatic amputation. The study was approved by The Research Ethics Committees (H-15003299)
and the Data Protection Agency (AHH-2014-018 03110).
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2.2. Settings and Participants
Patients were included at the Orthopaedic Amputation Unit at Copenhagen University Hospital,
Hvidovre, Denmark, between May 2015 and November 2016. The indication for amputation among
all patients was gangrene, due to poor circulation in the lower extremities. The inclusion criteria were:
Above 50 years of age and able to give an informed consent. Exclusion criteria were: Pathologic or
traumatic indications, intravenous drug-abuse, major surgical intervention within four weeks before
inclusion, amputation later than 14 days after inclusion, toe amputation, and parenteral nutrition use
at admission. For the current study, patients were also excluded if they received an ankle amputation,
had a diagnosis of acute kidney injury (AKI), or were in dialysis.
2.3. Study Data
Serum creatinine and cystatin C were measured at the Clinical Biochemical Department at
Copenhagen University Hospital, Hvidovre, Denmark, on a Roche Cobas® c 8000 701/702. Creatinine
was measured with a module instrument using the Roche, Basel, Switzerland, Creatinine Plus version
2 IDMS-traceable enzymatic assay (coefficient of variation 1.5%). Cystatin C was measured using the
Roche Cystatin C Tina-quant generation 2 particle-enhanced immunonephelometric assay (coefficient
of variation 2.2%). Both methods were standardized and validated in correspondence with Kidney
Disease Improving Global Outcomes (KDIGO) guidelines [9]. The neutrophil, gelatinase-associated
lipocalin (NGAL) was measured with the NGAL TestTM from Bioporto®, Copenhagen, Denmark, on a
Roche Cobas®, Basel, Switzerland, c 8000 c501/c502 particle-enhanced, turbidimetric immunoassay
(coefficient of variation 3.7%). C-reactive protein (CRP) and thyroid stimulating hormone (TSH) were
obtained from routine lab tests. TSH was measured on a Roche Cobas®, Basel, Switzerland, c8000 e602
competitive electrochemiluminescence immunoassay (coefficient of variation 3.8%). Reference interval
for TSH was 0.4–4.8 ng/mL.
Blood samples were obtained at inclusion (day −1), day of operation (day 0), and days 1, 3, 5, and
10 after amputation. Day 0 was defined as the before amputation blood sample. If this sample was
missing, then day −1 was used instead. In cases where no blood samples were available on day 5 or
10, the missing sample was replaced by the closest sample taken on day 6, 7, 8, 9, or 11.
The CKD-EPI equations were used to calculate eGFR, and eGFR was classified into one of five
categories according to the 2003 National Kidney Foundation Kidney Disease Outcomes Quality
Initiative Classification (K/DOQI) [26]. To investigate the complexity of kidney function, the number
of patients switching at least one kidney function category was calculated for each time interval.
To investigate the potential cases of undiagnosed AKI, we identified patients with an increase in
serum creatinine of ≥26.5 µmol/l within 48 hours or 50% within seven days as per 2012 KDIGO AKI
guidelines [19]. Three time intervals were used to determine creatinine change within 48 hours: day
0–1, day 1–3, and day 3–5. Five time intervals were used to determine creatinine change within seven
days: day 0–3, day 0–5, day 1–5, day 3–10, and day 5–10.
Weight and BMI were adjusted for a previous amputation at baseline. Muscle strength was
estimated by handgrip strength on a hand-held dynamometry device [27,28]. Smoking status and
comorbidities that were registered with International Statistical Classification of Diseases and Related
Health Problems 10th Revision (ICD-10) codes and obtained from patient records. Smoking status
was divided into current, previous, and never-smokers. Amputations were coded both by amputation
type and extent of muscle loss. Amputation type was either transtibial (KNGQ19) or transfemoral
(KNFQ19), and the extent of muscle loss was grouped as either major or minor muscle loss (Table 1).
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Table 1. Definition of minor and major muscle loss according to the amputation procedure.
Minor Muscle Loss Major Muscle Loss
Amputation at or below knee or
Transfemoral amputation with a prior transtibial
amputation on the same leg
Transfemoral amputation with no prior
amputations on the same leg
Medication information was obtained from the Danish electronic patient medication record and
included all medications administered from hospital admission to discharge, or 11 days post-operation,
whichever occurred first. Medication prescribing recommendations based on eGFR were obtained
from Renbase®. Medications were labeled, “renally-eliminated medications” if dose adjustments
were recommended at GFR ≤ 90 ml/min/1.73 m2. Total daily dose of renally-eliminated medications
administered post-operation was compared to dose recommendations in Renbase®, and a “dosing
discrepancy” was defined as any case in which total daily dose exceeded dose recommendations [3].
2.4. Statistical Analysis
CKD-EPI equations, both before, and after amputation were compared using the Friedman’s
test. To evaluate changes in eGFR from pre- to post-operation, mixed models were used with patient
identification modelled as a random effect, considering repeated measurement across investigation
days with a compound symmetry co-variance structure and a binary parameter, indicating whether
the measurements were before, or after, surgery as fixed effect. To investigate whether patients with
major muscle loss had a larger increase in eGFR than patients with minor muscle loss from pre- to
post-operation, an interaction term between the binary surgery parameter (before/after) and muscle
loss (minor/major) was included in the model. Finally, a fixed parameter for days after amputation
was included in a separate model to investigate whether the eGFR changes after amputation were
stable or simply a reflection of post-operative recovery. To investigate the robustness of the findings,
statistical tests were repeated after excluding patients with potential AKI.
Goodness of fit for the linear regression models was determined by visual inspection of a
histogram of residuals to test normal distribution, and a scatter plot of residuals versus predicted
values to test variance homogeneity. If needed, the dependent variable was transformed to improve
goodness of fit.
All calculations and statistical analyses were performed in SAS software, SAS Enterprise Guide,
Version 7.1. Copyright © SAS Institute Inc., Cary, NC, USA. Figures were created in RStudio 3.2.3.,
Integrated Development for R. RStudio, Inc., Boston, MA, USA. For all statistical tests, p ≤ 0.05 was
considered statistically significant.
3. Results
Data from a total of 42 patients were included in the Time to Eat Study. Four patients were
excluded in the present study due to ankle amputation (n = 3) or dialysis (n = 1). The median age
of participants was 75 years, and 29% were females. Table 2 includes information about baseline
characteristics. One patient died prior to day 3, and data from this patient were included when possible.
Five patients (13.2%) were identified with potential AKI, but none of these patients were diagnosed
with AKI during hospitalization.
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Table 2. Patient demographics.
Characteristics All Patients (n = 38) Patients with a MinorLoss of Muscle (n = 22)
Patients with a Major
Loss of Muscle (n = 16)
Age, years, median (range) 75 (53–95) 74 (53–89) 78 (60–95)
Age ≥ 80 years, n (%) 14 (37) 6 (27) 8 (50)
Sex, female, n (%) 11 (29) 4 (18) 7 (44)
Weight, kg, median (range) 67 (43–112) 77 (43–112) 60 (46–92)
BMI a, kg/m2, median (range) 22 (15–34) 23 (15–34) 22 (17–31)
BMI ≤ 18.5 kg/m2, n (%) 5 (13) 2 (9) 3 (19)
Kidney function b
Serum creatinine, mg/dL, median (range) 1.1 (0.5–3.8) 1.1 (0.5–3.8) 0.9 (0.6–2.1)
Serum cystatin C, mg/L, median (range) 1.5 (0.9–3.8) 1.5 (0.9–3.8) 1.4 (1.1–3.0)
Smoking, current, n (%) 17 (45) 11 (50) 6 (38)
TSH, ng/mL, median (range) c 1.7 (0.1–26.3) 1.7 (0.4–8.8) 1.7 (0–26.3)
CRP d, mg/dL, median (range) 88 (14–240) 68 (14–240) 98 (23–220)
Handgrip strength e, kg, median (range) 22 (4–40) 24 (9–38) 18 (4–40)
Low handgrip strength f, n (%) 21 (57) 11 (52) 10 (63)
Comorbidities
Diabetes, n (%) 17 (45) 10 (45) 7 (44)
Atherosclerosis, n (%) 29 (76) 15 (68) 14 (88)
Hypertension, n (%) 22 (58) 13 (59) 9 (56)
a: Missing values for three patients. If missing, then day 2 or 4, post-operation was used. b: All values read from day
of operation (day 0). If missing, values read from inclusion (day −1). c: Missing value for one patient. d: Missing
values for six patients. e: Missing value for one patient. All values read from day of operation (day 0). If missing,
values read from inclusion (day −1). f: Low handgrip strength was defined as < 26 kg for males and <16 kg for
females [29]. BMI: Body Mass Index. TSH: Thyroid stimulating hormone. CRP: C-reactive protein.
Prior to amputation, 30 (81%) patients were within TSH reference interval, whereas all patients
had a CRP greater than reference (>10 mg/dL) (Table 2). After amputation, the data from 38 patients
(day 1) revealed the median (range) serum creatinine and cystatin C values of 0.9 (0.4–3.8) mg/dL
and 1.3 (0.8–3.5) mg/L, whereas data from 37 patients (day 3) revealed values of 0.9 (0.4–2.7) mg/dL
and 1.3 (0.7–3.5) mg/L, respectively. After amputation (day 3) the patients had a median (range)
CRP of 120 (37–340) mg/dL and all patients had values greater than reference. Approximately half
of the patients had a NGAL value greater than 150 ng/mL, both before, and after, amputation with
a median (range) value of 159 (53–1053) and 147 (59–695) ng/mL before, and after, amputation,
respectively. GFR estimates were significantly different between CKD-EPICreatinine, CKD-EPICystatinC,
and CKD-EPICombined both before, and after, amputation (Friedman’s test: all p < 0.01) (Table 3).
Table 3. Estimated glomerular filtration rate (eGFR) from the Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) before, and after, amputation, and mean difference between equations.
Raw Data Mixed Models
Before,
Median (Range)
After,
Median (Range)
Mean Difference,
(95% CI) p
b
eGFRCreatinine, mL/min/1.73 m2 65 (15–103) 80 (22–107) 8.5 (5.1; 11.8) < 0.01
eGFRCystatinC mL/min/1.73 m2 38 (13–79) 51 (13–95) 6.1 (3.6; 8.6) < 0.01
eGFRCombined mL/min/1.73 m2 48 (13–86) 62 (16–100) 7.4 (4.7; 10) < 0.01
Friedmans test, p a < 0.01 < 0.01
a: Friedman’s test for the differences among eGFR based on creatinine, cystatin C, and the combination before and
after amputation, respectively. b: Mixed model test for the difference between before, and after, amputation for each
CKD-EPI equation, respectively.
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Figure 1 shows the individual estimated glomerular filtration rate (eGFR) curves for each patient
in the study during hospitalization.
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Figure 1. The level of eGFR during lower extremity amputation (n = 38). Light grey lines represent
each patient of which dashed lines are patients with potential acute kidney injury. Solid, black lines are
the medians.
3.1. Impact of Amputation on Kidney Function
GFR estimates for all equations increased significantly from pre- to post-operation (Table 3).
However, these increases were not significantly different among the three equations. Analyses
of interaction terms indicated that patients with major muscle loss had a larger increase in eGFR
compared to patients with minor muscle loss (p = 0.1 for eGFRCreatinine, p = 0.02 for eGFRCystatinC and
p = 0.03 for eGFRCombined). However, these differences were no longer significant when patients, with
potential AKI (n = 5), were excluded (all p values ≥ 0.14). Likewise the differences were insignificant
(all p values ≥ 0.07) if patients with potential AKI were calculated based on the post-operation
creatinine measurements only (n = 4).
The investigation of the changes after amputation as a reflection of post-operative recovery
showed that GFR estimates decreased significantly from post-operative day 5 to post-operative day 10
for both CKD-EPICystatinC (−6.8 mL/min/1.73m2, 95% CI: −9.7; −3.8, p < 0.01) and CKD-EPICombined
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(−4.5 mL/min/1.73 m2, 95% CI: −7.7; −1.3, p < 0.01). Similar results were obtained when patients
with potential AKI were excluded.
3.2. Prescribing Renally-Eliminated Medications
In the post-operative period, patients were prescribed a median (range) of 12 (6–25) medications,
including 7 (2–14) renally-eliminated medications. Morphine was the most commonly prescribed
medication, followed by oxycodone, dalteparin, and gabapentin. In total, at least one drug
was prescribed at higher than recommended dose according to Renbase® in 10.8% of patients
(12 prescriptions) according to eGFRCreatinine, 37.8% of patients (37 prescriptions) according to
eGFRCystatinC, or 17.6% of patients (16 prescriptions) according to eGFRCombined. When switching from
CKD-EPICreatinine to CKD-EPICystatinC, prescribing recommendations were particularly affected for
morphine, gabapentin, and metformin (Table 4). A similar pattern was observed when patients with
potential AKI were excluded. Notably, however, potential AKI was identified in 3 of 14 patients with
dosing discrepancies according to eGFRCreatinine or eGFRCombined, and 4 of 14 patients with dosing
discrepancies according to eGFRCystatinC.
Table 4. Number of patients with dosing discrepancies during hospitalization according to eGFR on
day 3 post-operation using CKD-EPI equations.
Active Substance
Patients with Dosing Discrepancies,
n (%) Total Patients
Prescribed,
n (%)
CKD-EPI equation
Creatinine Cystatin C Combined
Morphine (N02AA01) 2 (8) 6 (25) 3 (13) 24 (65)
Gabapentin (N03AX12) 3 (15) 7 (35) 4 (20) 20 (54)
Simvastatin (C10AA01) 0 (0) 1 (7) 0 (0) 14 (38)
Zopiclone (N05CF01) 1 (9) 2 (18) 1 (9) 11 (30)
Metformin (A10BA02) 2 (29) 5 (71) 3 (43) 7 (19)
Allopurinol (M04AA01) 0 (0) 1 (33) 0 (0) 3 (8)
Hydrochlorothiazide (C03AA03) 0 (0) 1 (33) 0 (0) 3 (8)
Mirtazapine (N06AX11) 0 (0) 1 (33) 0 (0) 3 (8)
Sitagliptin (A10BH01) 1 (33) 3 (100) 1 (33) 3 (8)
Bendroflumethiazide (C03AB01) 0 (0) 1 (50) 0 (0) 2 (5)
Cetirizine (R06AE07) 1 (50) 1 (50) 1 (50) 2 (5)
Ciprofloxacin (J01MA02) 0 (0) 0 (0) 0 (0) 2 (5)
Dabigatran (B01AE07) 0 (0) 1 (50) 0 (0) 2 (5)
Magnesium (A02AA04) 0 (0) 1 (50) 1 (50) 2 (5)
Metoclopramide (A03FA01) 0 (0) 1 (50) 0 (0) 2 (5)
Colchicin (M04AC01) 0 (0) 1 (100) 0 (0) 1 (3)
Venlafaxine (N06AX16) 1 (100) 1 (100) 1 (100) 1 (3)
Total, patients 4 (11) 14 (39) 6 (17) -
Total, patients without potential AKI (n = 31) 1 (3) 10 (28) 3 (8) -
3.3. Kidney Function Estimates During Hospitalization
Table 5 shows the number of patients whose kidney function classification changed during
hospitalization. With CKD-EPICreatinine, 6.1% to 16.2% of patients switched classification between days.
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Table 5. Patients who are re-classified (change or decrease) at least one category. Change refers to both
patients who are re-classified into a higher or lower category, whereas decrease refers to patients who
are re-classified into a lower category.
Day−1–Day 0 Day 0–Day 1 Day 1–Day 3 Day 3–Day 5 Day 5–Day 10
eGFRCreatinine, change, n (%)
decrease, n (%)
2 (6.1) 5 (13.2) 6 (16.2) 6 (16.2) 4 (12.5)
0 (0.0) 1 (2.6) 3 (8.1) 2 (5.6) 2 (6.3)
eGFRCystatinC, change, n (%)
decrease, n (%)
2 (6.1) 8 (21.1) 7 (18.9) 3 (8.3) 6 (18.8)
0 (0.0) 1 (2.6) 5 (13.5) 1 (2.8) 5 (15.6)
eGFRCombined, change, n (%)
decrease, n (%)
0 (0.0) 7 (18.4) 6 (16.2) 5 (13.9) 5 (15.6)
0 (0.0) 1 (2.6) 4 (10.8) 3 (8.3) 4 (12.5)
4. Discussion
In a cohort of amputation patients, we found that eGFR differs significantly between
CKD-EPICreatinine, CKD-EPICystatinC, and CKD-EPICombined both before, and after, amputation. These
differences may affect how patients are classified according to kidney function and, therefore, influence
the prescribing of renally-eliminated medications. We also found that eGFR increases significantly
after amputation for all CKD-EPI equations. However, we found no significant differences between
CKD-EPI equations in the degree of this effect. Finally, we identified fluctuations in GFR classification
during hospitalization, highlighting the challenge in prescribing renally-eliminated medications. These
findings stress the importance of further work to determine how to most accurately estimate kidney
function in this frail and vulnerable patient population.
4.1. eGFR Differences Before, and After, Amputation
The observed differences between creatinine- and cystatin C-based equations both before, and
after, amputation are two to four-fold larger in our population compared to studies in older hospitalized
patients without amputation [3,30–32]. The differences in our study are about the same size as
reported in the Northern Manhattan Study of 2,988 elderly patients with diverse racial and ethnic
backgrounds. Patients in this study had a mean age of 69.2 years, and 21% of patients had been
diagnosed with diabetes, 73% with hypertension and 24% with cardiac disease [33]. Patients in our
study are characterized by older age, decreased muscle mass, high inflammation, morbidity, fragility,
and post-operative stress [34,35]. Creatinine is dependent on muscle mass, sex, and age [20,36,37],
while cystatin C has been suggested to increase with inflammation [38] and other extra-renal factors
such as smoking, thyroid dysfunction, glucocorticoid use [3,36,37], and perhaps cardiovascular
diseases [39]. We have previously shown in elderly medical patients that age > 80 years, low handgrip
strength (<26 kg for males and <16 kg for females), CRP > 10 mg/dL, NGAL > 150 ng/mL, and
current smoking are significantly associated with differences in GFR estimates based on creatinine and
cystatin C [3]. These features are also common in our patient cohort, which could explain the significant
differences in eGFR based on creatinine and cystatin C before amputation. Another challenge with
using CKD-EPICreatinine in elderly patients is that the equation was developed in a patient cohort
where only 4% (n = 217) of participants were over 70 years old [40]. We expect that the high age,
low muscle mass, and inflammation in particular are responsible for the observed eGFR differences
between equations before amputation.
Thurlow et al. reported that eGFRCreatinine is influenced by amputation in young male soldiers
with a traumatic injury. The authors found that amputation led to an average eGFR increase of
20 mL/min/1.73 m2 for eGFRCreatinine, but only 11 mL/min/1.73 m2 for eGFRCombined and no
significant change for eGFRCystatinC [18]. We did not find that amputation affected eGFRCreatinine
more than eGFRCombined or eGFRCystatinC. This result is likely due to the nature of our patient
population. First, low muscle mass before amputation is a plausible explanation for the smaller
increase in eGFRCreatinine. This effect is supported by the significant differences between equations
J. Clin. Med. 2019, 8, 89 9 of 14
prior to amputation. Serum creatinine and cystatin C levels are also affected by non-renal factors, and it
is possible that creatinine or cystatin C did not reach steady state during our study period. Altogether,
these causes could have masked the effect of amputation on eGFRCystatinC, but it is not possible to
investigate the influence of these factors without directly measuring kidney function. Finally, our
results suggest that estimates of kidney function in elderly non-traumatic amputation patients are
highly complex regardless of which biomarker is used.
4.2. Choice of eGFR Equation and Biomarker to Amputation Patients
While our study cannot conclude anything about the accuracy of eGFR equations, it is clear that
the choice of equation has a major impact on prescribing recommendations for renally-eliminated
medications in our group of patients. More work is needed to determine the most accurate eGFR
equation for amputation patients, but it is unlikely that this equation will rely only on creatinine. The
CGCreatinine equation continues to be used in pharmacokinetic studies during drug development [11].
Due to the lack of performance of CGCreatinine [14], the alternative CKD-EPICreatinine equation is
sometimes used for drug prescribing in the clinic [41], and often preferred for the diagnosis and
treatment of kidney disease [19]. CGCreatinine is also impractical because it requires continuous weight
measurements. Weight measurements are typically not recorded in amputation patients because
they are difficult to obtain if the patient is immobilized, and are typically inaccurate due to unstable
fluid and food intake, edema, and blood loss. However, a weight measurement is necessary to
determine body surface area, which is used to convert eGFR based on CKD-EPI from normalized
units (mL/min/1.73 m2) to absolute units (mL/min). For drug development, the European Medicines
Agency only recommends eGFR in absolute values [42], while the US Food and Drug Administration
accept both normalized and absolute values [11]. The choice of eGFR unit can impact prescribing
recommendations—particularly in patients with small or large body surface area. Therefore, future
equations should rely less heavily on weight measurements, or utilize biomarkers which are less
dependent on weight. Ideally, these equations should be built on a panel of kidney biomarkers and
account for individual patient characteristics [37,43]. Alternatively, gold standard markers could be
made more accessible in clinical settings. This can be done by introducing single-plasma samples [44]
or dried blood spot testing [45], which should be considered as alternatives to eGFR.
4.3. Choice of eGFR Biomarkers Impact on Dosing Discrepancies
Our results suggest that switching between eGFRCreatinine, eGFRCystatinC, and eGFRCombined
would lead to different dosing recommendations for renally-eliminated medications, and this pattern
remained after patients with potential AKI were excluded. Dosing discrepancies occurred in 10.8% to
37.8% of patients depending on the choice of the eGFR equation. As expected, eGFRCystatinC yielded the
lowest eGFR and therefore the highest number of dosing discrepancies. Recent studies have similarly
identified that GFR estimates are lower with cystatin C-based equations compared to creatinine-based
equations in hospitalized patients without amputation and these differences had direct influences on
prescribing recommendations for renally-eliminated medications [3,30,31]. However, none of these
studies investigated the impact in patients undergoing amputation, making this study unique. The rate
of dosing discrepancies for CKD-EPICreatinine in our study population is high, but in concordance with
existing literature regarding prescribing practices in patients with impaired kidney function [4,46–49].
However, the observed increase in eGFR when switching to CKD-EPICystatinC had a greater impact on
dosing discrepancies compared to other studies of kidney function estimates in elderly patients [3].
Given the high number of renally-eliminated medications prescribed to amputation patients,
the risk of adverse drug effects due to dosing discrepancies reinforces the importance of obtaining
accurate kidney function estimates. Morphine was the most commonly prescribed renally-eliminated
medication in our cohort, and overdosing of morphine increases the risk of dangerous side effects,
including respiratory depression [50]. In a previous study, we also identified significant differences
in dosing of analgesics to the elderly using different eGFRCreatinine equations [51]. Dabigatran,
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gabapentin, and metformin are eliminated almost entirely by the kidneys in an unchanged form,
and overdosing of these medications in frail multi-morbid patients may lead to life-threatening
adverse drug reactions. However, these medications are often necessary for amputation patients and
are required for post-operative recovery. In cases where an accurate estimate of kidney function cannot
be obtained, we suggest switching to drugs, which are less dependent on renal function. In the case
of pain management, for example, fentanyl or another opioid analogue could be considered in place
of morphine.
The major differences between eGFR biomarkers in our study population also raise important
questions about the design of pharmacokinetic studies during drug development. We believe that
prescribing guidelines should be based on large pharmacokinetic characterization studies that use
a gold standard marker, as well as a panel of eGFR biomarkers with a wide range of demographic
representation. Data from these studies should be accessible for clinicians and displayed on medication
package inserts [3,13]. From a regulatory perspective, medication prescribers should use the eGFR
equation indicated in the summary of product characteristics (SPC). This equation is CGCreatinine for
the most currently marketed drugs [3,12]. However, clinicians should also know the limitations of
particular eGFR equations and recognize that pharmacokinetic characterization studies do not always
reflect what is relevant for the individual patient.
Finally, we observed clinically relevant fluctuations in GFR classification among amputation
patients during hospitalization. This finding highlights the challenge that clinicians face when
prescribing renally-eliminated medications to patients with unstable eGFR. While we have discussed
the risks of drug overdoses, drug under-dosing could lead to insufficient treatment of post-operative
pain, infection, and thrombosis. For these reasons, we recommend that clinicians are particularly
attentive to prescribing renally-eliminated medications in amputation patients and apply therapeutic
drug monitoring whenever possible. They should also consider whether patients should have their
kidney function measured with a gold standard until further evidence about the accuracy of GFR
estimates for amputation patients is available.
4.4. Strengths and Limitations
The primary strengths of this study were the availability of repeated measurements, which made
it possible to study the changes in kidney function over time, and the access to reliable medication
records. Generally, this study reflects a daily clinical problem in the surgery department and has
direct implications for clinical practice in amputation patients. However, we do not have creatinine
measurements after 10 days post-operation, so we are unable to determine whether creatinine or
cystatin C reach a steady-state during the study period. Our study also references dosing guidelines
from Renbase®, which is commonly used by Danish clinicians through pro.medicin.dk [6]. Renbase®
has also been referenced in several Northern European studies [3,4,47,51]. It contains prescribing
recommendations for more medications than other databases and is believed to reflect daily clinical
practice in Denmark. However, access to Renbase® requires a payment and is, therefore, not available
to all clinicians worldwide. Access to high quality databases is a well-known challenge and a limitation
for the interpretation of our results. Another limitation to our study is the lack of gold standard
markers for measuring kidney function, making it impossible to determine the absolute accuracy of
CKD-EPI equations. Finally, no urine samples were available for this study, so we could not evaluate
the third KDIGO criterion for assessing AKI. We only identified one patient with potential AKI based
on a change in creatinine from pre- to post-operation, and excluding this patient did not influence our
results. However, comparing creatinine measurements across amputation is not a sensitive determinant
of AKI, due to the loss of muscle mass.
5. Conclusions
Non-traumatic amputation of a lower extremity has a significant effect on eGFR based on
creatinine, cystatin C, or both. We found significant differences between eGFR from CKD-EPICreatinine,
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CKD-EPICystatinC, and CKD-EPICombined, both before, and after, amputation, and these differences
impact how renally-eliminated medications are prescribed. We also identified unstable eGFR
classification during hospitalization, thereby highlighting the risk of over- or under-dosing
renally-eliminated medications and highlighting the need to further study how kidney function
is most accurately determined in this vulnerable patient group.
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